Research shows that Bone Cancer cells express CB1, CB2 and TRPV1 receptors.
CB2 agonists as anandamide or THC affect the inflammatory process of Bone Cancer cells by modulating interleukin, tumor necrosis factor α and nuclear factor-κB expression and cofilin-1 protein (Hsu et al., 2007; Lu et al., 2015; Yang et al., 2015). This inflammatory process is involved in both pain regulation and cell death via apoptosis. TRPV1 and CB1 receptors are involved in cancer pain regulation (Kawamata et al., 2010).
Hsu, S.-S., Huang, C.-J., Cheng, H.-H., Chou, C.-T., Lee, H.-Y., Wang, J.-L., Chen, I.-S., Liu, S.-I., Lu, Y.-C., Chang, H.-T., et al. (2007).anandamide-induced Ca2+ elevation leading to p38 MAPK phosphorylation and subsequent cell death via apoptosis in human osteosarcoma cells. Toxicology 231, 21–29.
Kawamata, T., Niiyama, Y., Yamamoto, J., and Furuse, S. (2010).Reduction of Bone Cancer pain by CB1 activation and TRPV1 inhibition. J. Anesth. 24, 328–332.
Lu, C., Liu, Y., Sun, B., Sun, Y., Hou, B., Zhang, Y., Ma, Z., and Gu, X. (2015).Intrathecal Injection of JWH-015 Attenuates Bone Cancer pain Via Time-Dependent Modification of Pro-inflammatory Cytokines Expression and Astrocytes Activity in Spinal Cord. Inflammation.
Yang, L., Li, F.-F., Han, Y.-C., Jia, B., and Ding, Y. (2015).cannabinoid receptor CB2 is involved in tetrahydrocannabinol-induced anti-inflammation against lipopolysaccharide in MG-63 cells. Mediators Inflamm. 2015, 362126.